Kidney Transplant Recipients Clinical Trial
Official title:
A Prospective, Randomized, Multicenter, Open-Label, Pilot Study to Investigate Medication Adherence & Patient Reported Symptom Occurrence & Interference w/ Daily Life Comparing Envarsus XR® & Immediate Release Tacrolimus in Adult Renal Transplant Recipients (SIMPLE)
The purpose of this study is to compare once-daily tacrolimus extended-release (Envarsus XR®) to twice-daily immediate release tacrolimus to find out if people taking tacrolimus extended release (Envarsus XR®) report fewer side effects, increased medication compliance and higher scores on quality of life assessments compared to people taking twice daily tacrolimus immediate release.
Despite improvement in short-term graft outcomes in organ transplant, transplant patients still have to take on complex medication regimens to achieve current results. Adherence to these complex medications is an important problem in light of the potential risk of acute and chronic rejection and the associated burden of increased hospitalization, cost, and diminished quality of life that results from missed doses and poor overall drug taking. Part of the diminished quality of life is also tied to the bothersome symptoms patient feel after transplant. Most patients experience symptoms that relate to either the overall transplant immunosuppression or medication specific side effects. In the BENEFIT and BENEFIT-EXT trials, >60% of patients reported tiredness and lack of energy as an issue. Sleep problems, mood swings, restlessness, anxiety, depression, and concentration and memory difficulties appeared in approximately 50-60% of patients. In addition to these symptoms, >38% patients also reported numerous others side effects that have been strongly associated with calcineurin-inhibitors such as tacrolimus that include dizziness, muscle cramps, trembling hands, tingling in hands and feet, and headache. The investigators hypothesize that the use of once-daily Envarsus XR® could decrease some transplant- and tacrolimus-related adverse symptoms and potentially lead to improvement in quality of life and medication adherence when compared to twice-daily tacrolimus. In order to assess this hypothesis, a prospective, multi-center, randomized, open-label, pilot study to investigate medication adherence and patient reported symptom occurrence and interference with daily life comparing once-daily Envarsus XR® and twice-daily immediate release tacrolimus in adult renal transplant recipients (SIMPLE) is being proposed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01336296 -
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
|
Phase 4 | |
| Recruiting |
NCT05938712 -
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
|
Phase 2 | |
| Completed |
NCT00217100 -
A Multivitamin Comparison Study in Kidney Transplant Recipients.
|
Phase 3 | |
| Active, not recruiting |
NCT00199667 -
Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients
|
Phase 4 | |
| Terminated |
NCT01517984 -
Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation
|
Phase 2 | |
| Recruiting |
NCT04642833 -
Prostate Cancer in Renal Transplants Recipients
|
||
| Not yet recruiting |
NCT05293704 -
An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients
|
Phase 4 | |
| Completed |
NCT02555566 -
Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study
|
N/A | |
| Completed |
NCT01782586 -
Validation of Gene Expression Markers of Renal Allograft Functional Decline
|
||
| Enrolling by invitation |
NCT02042963 -
KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT)
|
N/A | |
| Not yet recruiting |
NCT05702398 -
Pilot Trial of Supplemental Vitamin A and Nicotinamide
|
Early Phase 1 | |
| Recruiting |
NCT05425498 -
The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients
|
N/A | |
| Completed |
NCT01889758 -
Pharmacokinetic Studies of Tacrolimus in Transplant Patients
|
Phase 4 | |
| Terminated |
NCT02268201 -
A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule
|
Phase 4 | |
| Recruiting |
NCT04965935 -
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
|
Phase 3 | |
| Recruiting |
NCT04444843 -
Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen
|
Phase 4 | |
| Completed |
NCT02392312 -
Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
|
||
| Completed |
NCT02639949 -
Measuring and Improving Medication Adherence in Kidney Transplant Patients
|
N/A | |
| Withdrawn |
NCT02058875 -
Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
|
Phase 4 | |
| Recruiting |
NCT01608412 -
A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus
|
Phase 4 |